Key facts
- This page summarizes Javier B. Szwarcberg's Form 4 filing for SPRUCE BIOSCIENCES, INC. (SPRB).
- 8 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 17 Dec 2025, 16:56.
Javier B. Szwarcberg - 11 Dec 2025 Form 4 Insider Report for SPRUCE BIOSCIENCES, INC. (SPRB)
- Reporting relationship
- CHIEF EXECUTIVE OFFICER, Director
- Issuer ticker
- SPRB
- Reported as of
- 11 Dec 2025
- Net transaction value
- -$109,711
- SEC form
- 4
- Accepted by SEC
- 17 Dec 2025, 16:56:43 UTC
- Prior SEC filing
- 12 Dec 2025
- Next SEC filing
- 05 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Samir Gharib, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Javier B. Szwarcberg filed Form 4 for SPRUCE BIOSCIENCES, INC. (SPRB) on 17 Dec 2025.
Change
- Previous filing in this sequence was filed on 12 Dec 2025.
- Current net transaction value: -$109,711.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001903669
Primary reporting owner
Szwarcberg Javier B.
- Relationship
- CHIEF EXECUTIVE OFFICER, Director
- Address
- C/O SPRUCE BIOSCIENCES, INC., 611 GATEWAY BOULEVARD, SUITE 740, SOUTH SAN FRANCISCO
- Signature
- /s/ Samir Gharib, Attorney-in-Fact
- Signature date
- 17 Dec 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,480
- Change %
- +11%
- Price
- $0.000000
- Shares after
- 14,478
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1, F2
SPRB
transaction
Common Stock
Tax liability
- Transaction value
- $60,664
- Shares
- -752
- Change %
- -5.2%
- Price
- $80.67
- Shares after
- 13,726
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F1
SPRB
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +1,196
- Change %
- +8.7%
- Price
- $0.000000
- Shares after
- 14,922
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F2, F3
SPRB
transaction
Common Stock
Tax liability
- Transaction value
- $49,047
- Shares
- -608
- Change %
- -4.1%
- Price
- $80.67
- Shares after
- 14,314
- Date
- 15 Dec 2025
- Ownership
- Direct
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
SPRB
transaction
Derivative
Employee Stock Option (right to buy)
Award
- Transaction value
- Shares
- +1,666
- Change %
- Price
- Shares after
- 1,666
- Date
- 11 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,666
- Exercise price
- $104.13
- Footnotes
- F4, F5, F6
SPRB
transaction
Derivative
Employee Stock Option (right to buy)
Disposed to Issuer
- Transaction value
- Shares
- -1,666
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 11 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,666
- Exercise price
- $344.25
- Footnotes
- F4, F5, F6
SPRB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,480
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 1,480
- Date
- 15 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,480
- Exercise price
- $0.000000
- Footnotes
- F1, F2
SPRB
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -1,196
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 2,392
- Date
- 15 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,196
- Exercise price
- $0.000000
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 6 footnotes
Footnote F1
On December 5, 2022, the Reporting Person was granted 5,920 time-based restricted stock units ("RSUs"), subject to a 4-year vesting schedule, with 25% of the total number of RSUs vested on December 15, 2023 (the "Annual Vesting Date") and 25% of the total number of RSUs to vest in annual installments on each anniversary of the Annual Vesting Date thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,480 RSUs vested, with 752 shares withheld for taxes, resulting in a net issuance of 728 shares.
Footnote F2
Each RSU represents a contingent right to receive one share of common stock of the Issuer.
Footnote F3
On December 14, 2023, the Reporting Person was granted a total of 9,658 RSUs. 50% or 4,784 of the total RSUs are performance-based and all vested on December 10, 2024. An addition of 50% or 4,784 of the total RSUs are time-based. 25% of which vested on December 15, 2024, and in equal annual installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). On December 15, 2025, 1,196 shares vested and 608 shares were withheld for taxes, resulting in a net issuance of 588 shares.
Footnote F4
The shares vest upon the achievement of specified performance goals, subject to the Reporting Person's Continuous Service (as defined in the Issuer's 2020 Equity Incentive Plan). 50% or 1,666 shares of the total shares vested on November 26, 2023. 50% or 1,666 shares of the total shares did not vest as the relevant performance goal was not achieved.
Footnote F5
The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on December 11, 2025 (the "Repricing Date"). The Option Repricing applies to options with exercise prices of $106.09 per share or greater held by employees and directors of the Issuer who remained in continuous service with the Company as of the Repricing Date.
Footnote F6
Pursuant to the Option Repricing, the exercise price of the repriced options has been amended to reduce the exercise price to $104.13 per share, the thirty (30)-day trailing volume-weighted average price of the Common Stock on the Nasdaq Capital Market on the Repricing Date. However, if an optionholder exercises a repriced option before the end of a retention period of one year (which period may be shorter in certain circumstances), such optionholder will be required to pay the original exercise price per share of such repriced option. No other changes were made to the repriced options in connection with the Option Repricing, including with respect to the vesting schedules, expiration dates or number of shares underlying such repriced options.